COMPANY PROFILE

Kumquat Biosciences

Explore full profile

Innovative oncology therapies translating breakthrough science into life-changing cancer treatments

San Diego, United StatesFounded 2018Biotech & Life Sciences

Valuation $100–500M Latest valuation · 2021

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Kumquat Biosciences

Kumquat Biosciences is a biotechnology company dedicated to developing innovative therapies aimed at providing sustainable and life-changing benefits to cancer patients. The company focuses on translating breakthrough scientific discoveries into first-in-class therapeutics. Kumquat Biosciences operates in the oncology market, targeting cancer treatment and care. The business model revolves around drug discovery and development, leveraging the expertise of an accomplished team and distinguished scientific founders with a proven track record in oncology. Revenue is generated through the development and commercialization of proprietary cancer therapies, as well as potential partnerships and collaborations with other pharmaceutical companies. Kumquat Biosciences serves patients, healthcare providers, and the broader medical community by offering advanced treatment options that address unmet medical needs in oncology.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2018
Headquarters: San Diego, United States
Employees: 81
Open positions: 1
Dealroom signal: 76.2/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Latest news

Press, funding announcements and product moves mentioning Kumquat Biosciences.

See all news

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	Jul 2021	$70M	$280M	Loxo Oncology	—
LATE VCOther financing	Feb 2021	$50M	$200M	Undisclosed	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Kumquat Biosciences website traffic

Latest recorded traffic for Kumquat Biosciences is 1.1K monthly website visits, up 19.6% over the last three months. Kumquat Biosciences's team declined 2.4% over the past year.

Latest monthly visits1.1K 3-month web change+19.6% 1-year team growth-2.4%

Monthly website visitsAug 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Clinical Trial Manager (CTM)San Diego, California, United States, Northern America, Americas · CSM & Support · Sep 5, 2026 Chief Financial OfficerSan Diego, CA · C-Level · Aug 27, 2026 Senior Medical ConsultantSan Diego, California, United States, Northern America, Americas · Other · Aug 22, 2026 Head of Clinical OperationsSan Diego, CA · Other · Jul 14, 2026 Manager, Clinical Trial Finance and FP&ASan Diego, California, United States · Finance · Jan 16, 2026

5 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
HTHarness TherapeuticsA private biotechnology company, headquartered in Cambridge-UK, focused on the development of a novel class of therapeutic RNAs	Babraham, United Kingdom	Operational	5	$35M	$90M
KIKimialysDeveloper of an analytical device intended to offer products based on innovative surface chemistry in the field of biosensors	Paris, France	Operational
SISideROSFocused on accelerated development of innovative small molecules targeting tumour cells metabolism in high-risk cancers	Paris, France	Closed
ANAntegenesGenetic tests for personalized cancer risk prevention	Tartu, Estonia	Operational
BPBrenus PharmaProducing the widest panel of tumor associated antigens and resistance markers with a chemical labeling enable to induce cell death by patients' immune system	Clermont-Ferrand, France	Operational
EBExeliom BiosciencesDeveloping single bacterial strain drug candidates to deliver first-in-class microbiome-based therapeutics	Dijon, France	Operational
MTModalis TherapeuticsEpigenetic gene modulation therapies for genetic disorders	Cambridge, United States	Operational
HPHcs PharmaA company specializing in cell imaging	Loos, France	Operational